# VESALIUS-CV (NCT03872401)

> Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03872401
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Coronary Heart Disease (CHD)
- Interventions: Evolocumab; Placebo
- Enrollment: 12301
- Primary outcome: Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
- Primary outcome: Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First

## Commentary we found

- Podcasts: 5
- YouTube: 4
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=vesalius-cv-nct03872401

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03872401", "email": "<work email>"}; the inbox owner confirms by the emailed link.